The Measles drugs in development market research report provides comprehensive information on the therapeutics under development for Measles, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Measles. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Measles and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Measles by 17 companies/universities/institutes. The top development phase for Measles is preclinical with four drugs in that stage. The Measles pipeline has 14 drugs in development by companies and four by universities/ institutes. Some of the companies in the Measles pipeline products market are: Beijing Minhai Biotechnology, Vaxxas and Daiichi Sankyo.
The key targets in the Measles pipeline products market include RNA Polymerase.
The key mechanisms of action in the Measles pipeline product include RNA Polymerase Inhibitor with one drug in Preclinical. The Measles pipeline products include four routes of administration with the top ROA being Subcutaneous and four key molecule types in the Measles pipeline products market including Vaccine, and Live Attenuated Vaccine.
Measles overview
Measles is a highly infectious viral disease. The virus lives in the mucus of the nose and throat of people with this infection. Physical contact, coughing, and sneezing can spread the infection. Symptoms of measles are high temperature, sore eyes (conjunctivitis), and a runny nose, which usually occur first; small white spots usually develop inside the mouth a day or so later, with diarrhea and vomiting.
For a complete picture of Measles’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
